Press Releases

For press releases issued prior to June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc., please visit Innoviva, Inc.

Date Title  
07/31/19
- Late-stage clinical studies of TD-1473 and ampreloxetine progressing - Phase 1 results including biomarker data in asthmatics for lung-selective inhaled pan-JAK inhibitor TD-8236 expected in September 2019 - Strong customer acceptance and brand performance of YUPELRI® (revefenacin) inhalation
07/25/19
DUBLIN , July 25, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today announced that it will release financial results for the period ended June 30, 2019 and provide a business update prior to market open on Wednesday, July 31, 2019 .
07/22/19
Durable reductions in OHSA and OHDAS Composite scores reflect improvements in overall symptoms and daily activity throughout 20 weeks of treatment Findings consistent with previously reported reductions in the cardinal symptom of dizziness as measured by OHSA #1 and supportive of ongoing
06/18/19
Durable improvements in neurogenic orthostatic hypotension (nOH) symptom severity sustained over 20 weeks of treatment; symptom severity returns to baseline with treatment discontinuation Data supportive of ongoing registrational Phase 3 program in symptomatic nOH DUBLIN , June 18, 2019
06/14/19
First and only once-daily, nebulized bronchodilator has potential to address unmet needs of China's nearly 100 million chronic obstructive pulmonary disease (COPD) patients DUBLIN and HERTFORDSHIRE, England and PITTSBURGH , June 14, 2019 /PRNewswire/ -- Theravance Biopharma Ireland Limited, a
06/04/19
Experienced Life Science Industry Executive with Strong Track Record of Long-Term Value Creation and Broad Therapeutic Expertise DUBLIN , June 4, 2019 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today announced the appointment of Andrew
05/21/19
Data Demonstrate Signals of Clinical, Histologic and Biomarker Activity Suggesting Localized Target Engagement following Four Weeks of Treatment in Patients with Moderately-to-Severely Active Ulcerative Colitis Additional Findings Demonstrate Minimal Systemic Exposure and No Evidence of Systemic
05/20/19
Post-Hoc Analysis Highlights the Potential Role of YUPELRI in the COPD Treatment Paradigm Additional Analyses Demonstrate Commitment to Further Scientific Understanding of COPD DUBLIN and HERTFORDSHIRE, England and PITTSBURGH , May 20, 2019 /PRNewswire/ -- Theravance Biopharma, Inc.
05/14/19
Presentation to Highlight Positive Data Demonstrating Clinical and Biomarker Activity Suggesting Localized Target Engagement and Minimal Systemic Exposure Following Four Weeks of Treatment in Patients with Moderately-to-Severely Active Ulcerative Colitis DUBLIN , May 14, 2019 /PRNewswire/ --
05/07/19
- Late-stage clinical studies of TD-1473 and ampreloxetine underway - Phase 1 results including biomarker data in asthmatics for lung-selective inhaled pan-JAK inhibitor TD-8236 expected in third quarter 2019 - Product launch of YUPELRI® (revefenacin) inhalation solution progressing in partnership